MA27682A1 - Compositions de valdecoxib a delitement intra-oral - Google Patents
Compositions de valdecoxib a delitement intra-oralInfo
- Publication number
- MA27682A1 MA27682A1 MA27586A MA27586A MA27682A1 MA 27682 A1 MA27682 A1 MA 27682A1 MA 27586 A MA27586 A MA 27586A MA 27586 A MA27586 A MA 27586A MA 27682 A1 MA27682 A1 MA 27682A1
- Authority
- MA
- Morocco
- Prior art keywords
- valdecoxib
- compositions
- intraoral delivery
- valdecoxib compositions
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
DEPOSANT Société dite : PHARMACIA CORPORATION REVENDICATION DE PRIORITES US 26 Septembre 2001 60/325,356 Compositions de valdécoxib à délitement intra-oral Des comprimés de valdécoxib à délitement oral, fondant rapidement, et des procédés pour la préparation de ces formes posologiques sont proposés. Les compositions sont utiles dans le traitement ou la prophylaxie de troubles et d'affections à médiation par la cyclo-oxygénase-2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32535601P | 2001-09-26 | 2001-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27682A1 true MA27682A1 (fr) | 2006-01-02 |
Family
ID=23267542
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27587A MA27542A1 (fr) | 2001-09-26 | 2004-03-24 | Compositions a delitement intra-oral, acceptables du point de vue organoleptique. |
MA27586A MA27682A1 (fr) | 2001-09-26 | 2004-03-24 | Compositions de valdecoxib a delitement intra-oral |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27587A MA27542A1 (fr) | 2001-09-26 | 2004-03-24 | Compositions a delitement intra-oral, acceptables du point de vue organoleptique. |
Country Status (25)
Country | Link |
---|---|
US (1) | US20030181501A1 (fr) |
EP (2) | EP1429736A2 (fr) |
JP (2) | JP2005512964A (fr) |
KR (2) | KR20040044990A (fr) |
CN (2) | CN1703203A (fr) |
AP (2) | AP2004002999A0 (fr) |
AR (1) | AR037239A1 (fr) |
BR (2) | BR0212778A (fr) |
CA (2) | CA2461044A1 (fr) |
CO (2) | CO5570659A2 (fr) |
EA (2) | EA200400357A1 (fr) |
EC (1) | ECSP045029A (fr) |
GE (1) | GEP20063856B (fr) |
HK (1) | HK1079988A1 (fr) |
IL (2) | IL160855A0 (fr) |
IS (2) | IS7177A (fr) |
MA (2) | MA27542A1 (fr) |
MX (2) | MXPA04002798A (fr) |
NO (2) | NO20041258L (fr) |
OA (2) | OA12707A (fr) |
PL (2) | PL369298A1 (fr) |
TN (2) | TNSN04045A1 (fr) |
WO (2) | WO2003026697A2 (fr) |
YU (1) | YU34804A (fr) |
ZA (2) | ZA200401953B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002557A1 (fr) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations |
US20050186271A1 (en) * | 2004-02-24 | 2005-08-25 | Sheskey Paul J. | Process for dispersing a fluid in a mass of solid particles |
KR20070040389A (ko) * | 2004-08-10 | 2007-04-16 | 아지노모토 가부시키가이샤 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
CN101115469A (zh) * | 2004-12-28 | 2008-01-30 | 卫材R&D管理有限公司 | 速崩片及其制造方法 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
TW200732000A (en) * | 2005-12-20 | 2007-09-01 | Eisai R&D Man Co Ltd | Orally disintegrating table comprising fat-soluble drug |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865743B2 (en) * | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
WO2007087188A2 (fr) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Comprimes et granules au gout masque |
US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
WO2007142811A2 (fr) * | 2006-05-19 | 2007-12-13 | Somaxon Pharmaceuticals, Inc. | Formulations de doxépine à faible dose, incluant des formulations buccales, sublinguales et à dissolution rapide, et leurs utilisations pour traiter l'insomnie |
JP2010529071A (ja) * | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 速崩性錠剤製造のための医薬製剤 |
CA2686964A1 (fr) * | 2007-06-06 | 2008-12-11 | Basf Se | Preparation pharmaceutique pour produire des comprimes a delitement rapide |
CN101686931B (zh) * | 2007-06-06 | 2013-06-19 | 巴斯夫欧洲公司 | 用于制备可咀嚼片剂和锭剂的药物配制剂 |
WO2008148733A2 (fr) * | 2007-06-06 | 2008-12-11 | Basf Se | Préparation pharmaceutique pour produire des comprimés à délitement rapide |
KR101606944B1 (ko) * | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
EP2268268A2 (fr) * | 2008-03-24 | 2011-01-05 | Wockhardt Research Centre | Compositions orodispersibles de rhéine ou de diacéréine |
US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
KR101704156B1 (ko) * | 2008-11-25 | 2017-02-07 | 미쓰비시 타나베 파마 코퍼레이션 | 구강 내 속붕괴성정을 제조하기 위한 혼합물 |
WO2010144865A2 (fr) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Procédés de traitement de troubles gastro-intestinaux |
US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
CA2178686A1 (fr) * | 1995-06-13 | 1996-12-14 | Leslie G. Humber | Formulations orales de s(+)-etodolac |
AU6964396A (en) * | 1995-10-20 | 1997-05-07 | Pharmacia & Upjohn Company | Blister package |
CN1140267C (zh) * | 1996-05-17 | 2004-03-03 | 麦克公司 | 治疗环加氧酶-2介导的疾病的每天一次的组合物 |
EP0863134A1 (fr) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2 |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
DK1309315T3 (da) * | 2000-08-18 | 2006-10-09 | Pharmacia Corp | Hurtigt disintegrerende oral valdecoxib-formulering |
CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
-
2002
- 2002-09-23 KR KR10-2004-7004373A patent/KR20040044990A/ko not_active Application Discontinuation
- 2002-09-23 JP JP2003530260A patent/JP2005512964A/ja not_active Withdrawn
- 2002-09-23 YU YU34804A patent/YU34804A/sh unknown
- 2002-09-23 JP JP2003530331A patent/JP2005506987A/ja not_active Withdrawn
- 2002-09-23 EP EP02773522A patent/EP1429736A2/fr not_active Withdrawn
- 2002-09-23 GE GE5525A patent/GEP20063856B/en unknown
- 2002-09-23 CN CNA028189078A patent/CN1703203A/zh active Pending
- 2002-09-23 EA EA200400357A patent/EA200400357A1/ru unknown
- 2002-09-23 BR BR0212778-4A patent/BR0212778A/pt not_active IP Right Cessation
- 2002-09-23 BR BR0212861-6A patent/BR0212861A/pt not_active IP Right Cessation
- 2002-09-23 IL IL16085502A patent/IL160855A0/xx unknown
- 2002-09-23 MX MXPA04002798A patent/MXPA04002798A/es unknown
- 2002-09-23 KR KR10-2004-7004334A patent/KR20040058189A/ko not_active Application Discontinuation
- 2002-09-23 US US10/252,222 patent/US20030181501A1/en not_active Abandoned
- 2002-09-23 MX MXPA04002652A patent/MXPA04002652A/es unknown
- 2002-09-23 EP EP02775948A patent/EP1490035A1/fr not_active Withdrawn
- 2002-09-23 OA OA1200400083A patent/OA12707A/en unknown
- 2002-09-23 OA OA1200400082A patent/OA13060A/en unknown
- 2002-09-23 CN CNA028211413A patent/CN1633281A/zh active Pending
- 2002-09-23 AP APAP/P/2004/002999A patent/AP2004002999A0/en unknown
- 2002-09-23 EA EA200400352A patent/EA200400352A1/ru unknown
- 2002-09-23 IL IL16084802A patent/IL160848A0/xx unknown
- 2002-09-23 CA CA002461044A patent/CA2461044A1/fr not_active Abandoned
- 2002-09-23 PL PL02369298A patent/PL369298A1/xx not_active Application Discontinuation
- 2002-09-23 AP APAP/P/2004/002998A patent/AP2004002998A0/en unknown
- 2002-09-23 WO PCT/US2002/030048 patent/WO2003026697A2/fr active Application Filing
- 2002-09-23 PL PL02369297A patent/PL369297A1/xx not_active Application Discontinuation
- 2002-09-23 WO PCT/US2002/030161 patent/WO2003026623A1/fr active Application Filing
- 2002-09-23 CA CA002461630A patent/CA2461630A1/fr not_active Abandoned
- 2002-09-26 AR ARP020103627A patent/AR037239A1/es unknown
-
2004
- 2004-03-10 ZA ZA200401953A patent/ZA200401953B/en unknown
- 2004-03-11 IS IS7177A patent/IS7177A/is unknown
- 2004-03-11 IS IS7178A patent/IS7178A/is unknown
- 2004-03-23 TN TNP2004000045A patent/TNSN04045A1/fr unknown
- 2004-03-23 EC EC2004005029A patent/ECSP045029A/es unknown
- 2004-03-24 TN TNP2004000047A patent/TNSN04047A1/fr unknown
- 2004-03-24 MA MA27587A patent/MA27542A1/fr unknown
- 2004-03-24 MA MA27586A patent/MA27682A1/fr unknown
- 2004-03-25 NO NO20041258A patent/NO20041258L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402364A patent/ZA200402364B/xx unknown
- 2004-03-26 CO CO04028410A patent/CO5570659A2/es not_active Application Discontinuation
- 2004-03-26 CO CO04028409A patent/CO5570684A2/es not_active Application Discontinuation
- 2004-04-15 NO NO20041532A patent/NO20041532L/no not_active Application Discontinuation
-
2006
- 2006-01-04 HK HK06100055.6A patent/HK1079988A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27682A1 (fr) | Compositions de valdecoxib a delitement intra-oral | |
TR200002207T1 (tr) | Slekoksib bileşikleri. | |
MA26700A1 (fr) | FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. | |
BR0011867A (pt) | Preparação farmacêutica de levodopa/carbidopa/entacapona | |
FR2727016B1 (fr) | Compositions pharmaceutiques a base d'ondansetron | |
HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
WO2003047519A3 (fr) | Composition pharmaceutique pour comprime annulaire compresse et comprime triture moule pour administration intra-orale et par voie buccale | |
HUP0302068A2 (hu) | COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203844A2 (hu) | Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
HUP0402178A2 (hu) | 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
HUP0204511A2 (en) | Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas | |
FR2712495B1 (fr) | Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant. | |
BR9912588A (pt) | Prevenção de recorrência de enxaqueca | |
RU2001124802A (ru) | Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств | |
SE9903995D0 (sv) | New combination | |
MA27543A1 (fr) | Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation. | |
MA27136A1 (fr) | Association nouvelle. | |
GEP20032969B (en) | Sertraline Oral Concentrate | |
WO2002055062A3 (fr) | Comprime pharmaceutique comprenant du mesylate de paroxetine | |
AR052138A1 (es) | Composicion farmaceutica de liberacion lenta que comprende (+)-(2s,3s)-2-(3-clorofenil)-3,5,5-trimetil-2- morfolinol y su uso para la elaboracion de un medicamento | |
Golub et al. | A “Point by Point” Statement on Periodontal Host Modulation Therapy: SAFETY FIRST | |
Babaloo et al. | Comparison of analgesic effects of novafen and ibuprofen after periodontal surgeries | |
MXPA04004290A (es) | Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido. | |
DK1448184T3 (da) | Anvendelse af propionyl-L-carnitin eller et af dets farmakologisk acceptable salte til fremstilling af en medicin til behandling af Peyronies sygdom |